Alpha DaRT — Initial data
Q3 2026
Alpha Tau is targeting completion of accrual in Q3 2026, with initial results approximately six months later.Source filing
ORMP biotech catalysts & pipeline
ORAMED PHARMACEUTICALS INC · Data as of 2026-09-08
Upcoming catalysts
Alpha DaRT — Topline data
Sep 2026–Apr 2027
Alpha Tau has begun submitting modules of its Modular Pre-Market Approval (PMA) application to the FDA and has finished treating patients in its ReSTART pivotal trial, with top-line data from the trial expected in late 2026 or early 2027.Source filing
Alpha DaRT — NDA/BLA submission
Late 2026
As of January 2026, Alpha Tau targeted completion of patient recruitment in Q1 2026 and has begun submitting modules of its Modular Pre-Market Approval (PMA) application to the FDA, with expected completion of the full submission by year-end 2026.Source filing